The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVedanta Resources Broker Ratings (VED)

  • There is currently no data for VED

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker Recommendations for Vedanta Resources (VED)

Date Broker Recommendation Old Target New Target Rating Type
14-Aug-13Goldman SachsBuy1,380.001,500.00Reiteration
08-Aug-13Liberum CapitalHold--Downgrade
06-Aug-13JefferiesHold1,200.001,350.00Reiteration
16-Jul-13RBC Capital MarketsUnderperform1,200.001,100.00Downgrade
10-Jul-13Goldman SachsBuy1,415.001,400.00Reiteration
25-Jun-13Morgan StanleyEqual Weight1,260.001,140.00Reiteration
25-Jun-13DeutscheBuy1,344.001,117.00Reiteration
31-May-13Goldman SachsNeutral1,415.001,415.00Reiteration
23-May-13Credit SuisseOutperform1,500.001,500.00Reiteration
14-May-13BarclaysEqual Weight--Downgrade
13-May-13JP Morgan CazenoveOverweight1,500.001,500.00Reiteration
13-May-13DeutscheHold1,230.001,290.00Downgrade
24-Apr-13Societe GeneraleSell949.00967.00Reiteration
22-Apr-13HSBCNeutral1,310.001,280.00Reiteration
15-Apr-13CitigroupNeutral1,200.001,200.00Reiteration
15-Apr-13Bank of AmericaBuy1,320.001,320.00Reiteration
10-Apr-13JP Morgan CazenoveOverweight1,500.001,500.00Reiteration
10-Apr-13DeutscheBuy1,485.001,270.00Reiteration
05-Apr-13JefferiesHold1,150.001,150.00Reiteration
04-Apr-13Bank of AmericaBuy1,300.00-Upgrade
03-Apr-13Credit SuisseOutperform1,500.001,300.00Reiteration
20-Mar-13JefferiesHold1,150.001,150.00Reiteration
20-Mar-13Dahlman Rose & CoBuy1,485.001,485.00Reiteration

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.